These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 29383028)
1. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Sugano K Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028 [TBL] [Abstract][Full Text] [Related]
2. Vonoprazan fumarate for the management of acid-related diseases. Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473 [TBL] [Abstract][Full Text] [Related]
4. The role of vonoprazan in patients with erosive esophagitis. Zhang M; Xiao Y; Chen M Therap Adv Gastroenterol; 2022; 15():17562848221122623. PubMed ID: 36117573 [TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y Digestion; 2017; 95(4):281-287. PubMed ID: 28501868 [TBL] [Abstract][Full Text] [Related]
6. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. Shirai Y; Kawami N; Iwakiri K; Kuwana M J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943 [TBL] [Abstract][Full Text] [Related]
7. Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review. Domingues G; Chinzon D; Moraes-Filho JPP; Senra JT; Perrotti M; Zaterka S Prz Gastroenterol; 2023; 18(1):47-55. PubMed ID: 37007753 [TBL] [Abstract][Full Text] [Related]
14. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. Marabotto E; Ziola S; Savarino V; Giannini EG; Furnari M; Bodini G; Zingone F; Ghisa M; Barberio B; Zentilin P; Savarino E Clin Exp Gastroenterol; 2020; 13():99-104. PubMed ID: 32346304 [TBL] [Abstract][Full Text] [Related]
15. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636 [TBL] [Abstract][Full Text] [Related]
17. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Kobayashi Y; Lefor AK; Yamamoto H Biomed Rep; 2017 Sep; 7(3):231-235. PubMed ID: 28894571 [TBL] [Abstract][Full Text] [Related]
18. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. Oshima T; Miwa H J Neurogastroenterol Motil; 2018 Jul; 24(3):334-344. PubMed ID: 29739175 [TBL] [Abstract][Full Text] [Related]
19. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. Habu Y Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490 [TBL] [Abstract][Full Text] [Related]